Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs

Cancer Biology and Therapy

Volumn 5, Issue 4, 2006, Pages 380-385

  Wang, Haijuan ^a   Qian, Haili ^a   Yu, Jian ^b   Zhang, Xueyan ^a   Zhang, Lin ^b   Fu, Ming ^a   Liang, Xiao ^a   Zhan, Qimin ^a   Lin, Chen ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; Apoptosis; Chemosensitivity; Esophageal cancer; Gene therapy; p53; PUMA

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; P53 UPREGULATED MODULATOR OF APOPTOSIS; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; DRUG EFFICACY; DRUG INHIBITION; ESOPHAGUS CANCER; HUMAN;

EID: 33646415691     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.4.2477     Document Type: Article

References (31)

1. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993; 54:402-7.
2. Coia LR, Sauter ER. Esophageal cancer. Curr Probl Cancer 1994; 18:189-247.
3. Sugimachi K, Ohno S, Matsuda M, Mori M, Matsuoka H, Kuwano H. Clinicopathologic study of early stage esophageal carcinoma. Surgery 1989; 105:706-10.
4. Kato H. Diagnosis and treatment of esophageal neoplasms. Jpn J Cancer Res 1995; 86:993-1009.
5. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994; 78:539-42.
6. Shimada H, Matsubara H, Ochiai T. p53 gene therapy for esophageal cancer. J Gastroenterol 2002; 37:87-91.
7. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7:673-82.
8. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683-94.
9. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003; 4:321-8.
10. Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chittenden T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 2001; 98:11318-23.
11. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100:1931-6.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
13. Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. J Surg Res 2003; 113:50-5.
14. 1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus. Int J Oncol 2001; 18:157-63.
15. Tanaka H, Shibagaki I, Shimada Y, Wagata T, Imamura M, Ishizaki K. Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: Increased frequency and different spectrum of mutations from primary tumors. Int J Cancer 1996; 65:372-6.
16. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
17. Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K, Nukiwa T. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 2000; 157:105-12.
18. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 1999; 44:143-51.
19. Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA, Shimokata K. Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of nonsmall cell lung cancer cells. Cancer Gene Ther 2000; 7:537-44.
20. Song K, Cowan KH, Sinha BK. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res 1999; 11:153-9.
21. Eisold S, Ridder R, Burguete T, Schmidt J, Klar E, Herfarth C, Doeberitz M. Synergistic effect of p53 adenovirus-mediated gene therapy and 5-FU-chemotherapy against pancreatic cancer cells in vivo. Cancel Gene Ther 1999; 6:s5.
22. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
23. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
24. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14.
25. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human apillomavirus-associated cancer. Nature 1998; 393:229-34.
26. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994; 68:4262-73.
27. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
28. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.
29. Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J. Induction of p53 upregulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 2005; 11:1863-9.
30. Ito H, Kanzawa T, Miyoshi T, Hirohata S, Kyo S, Iwamaru A, Aoki H, Kondo Y, Kondo S. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther 2005; 16:685-98.
31. Karst AM, Dai DL, Martinka M, Li G. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 2005; 24:1111-6.